| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2013: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
We proved the common view that a bone fragility increases in patients with chronic kidney disease by a modern clinical study method. In vivo experimental studies revealed that the contribution of abnormal systemic mineral metabolism to the bone fragility was quite limited while uremic toxins directly and reversibly modified bone material properties that lead a deterioration of bone elastic mechanical properties in uremic condition.
From these findings, we proposed a new disease concept of "uremic osteoporosis", which is clearly distinct from CKD-MBD. The concept of direct modification of bone material properties by uremic toxins would not only help improving the clinical practice pattern on bone in patients with chronic kidney disease, but also provide a possible new key to elucidate the pathophysiology of senile osteoporosis.
|
